A Phase II Open Label Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Sponsor: Takeda Oncology
Enrolling: Male and Female Patients
IRB Number: AAAR5196
U.S. Govt. ID: NCT03838692
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a study designed for patients with medullary thyroid cancer. Treatment will consist of a drug called Ponatinib. Ponatinib is an investigational agent that blocks abnormal cancer proteins and therefore harms cancer cells. It was recently approved by the Food and Drug Administration for leukemia treatment, but is not approved for medullary thyroid cancer treatment.
This study is closed
Antonio Fojo, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with localized or metastatic unresectable medullary thyroid cancer? Yes No
Has your cancer progressed after treatment with cabozantinib or vandetanib? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator